Pacific Capital Partners Ltd Sells 15,000 Shares of Danaher Corporation $DHR

Pacific Capital Partners Ltd lowered its position in Danaher Corporation (NYSE:DHR) by 42.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,000 shares of the conglomerate’s stock after selling 15,000 shares during the period. Danaher accounts for 3.7% of Pacific Capital Partners Ltd’s portfolio, making the stock its 9th largest holding. Pacific Capital Partners Ltd’s holdings in Danaher were worth $3,951,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after buying an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Danaher by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock worth $1,800,614,000 after buying an additional 194,466 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Danaher by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate’s stock worth $1,303,163,000 after buying an additional 579,046 shares during the period. Finally, Invesco Ltd. grew its stake in Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the topic of several recent analyst reports. Evercore ISI dropped their target price on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Guggenheim reiterated a “buy” rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Barclays reissued an “overweight” rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $246.35.

Insider Buying and Selling

In related news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Down 2.6%

DHR opened at $190.07 on Friday. The stock has a market capitalization of $136.10 billion, a price-to-earnings ratio of 40.44, a P/E/G ratio of 2.72 and a beta of 0.75. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The business has a 50 day moving average of $201.21 and a 200-day moving average of $198.83. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period last year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.